ProteomAKI
Research type
Research Study
Full title
Identification of biomarkers and their association with mortality in patients with advanced cirrhosis with and without acute kidney injury. A pilot study.
IRAS ID
304336
Contact name
Juan Acevedo Haro
Contact email
Sponsor organisation
University Hospital Plymouth NHS Trust
Duration of Study in the UK
0 years, 6 months, 0 days
Research summary
Alcohol misuse and obesity are increasingly prevalent in our population and hence, they are two of the current main National Public Health priorities. Both factors lead, over years, to the development of liver scarring (cirrhosis). Thus, the number of patients diagnosed with liver cirrhosis is increasing year by year. When the scarring stage is advanced it could lead to severe complications (or decompensations) such as accumulation of fluid in the abdomen (ascites). Patients with decompensated cirrhosis have a high short-term mortality. When patients have ascites and their kidneys are also malfunctioning the mortality is even higher. The most commonly employed method to assess renal function in patients with cirrhosis is the measurement of creatinine levels in plasma, but the production of creatinine depends on muscle mass, which is usually reduced in patients with advanced cirrhosis and thus, it is not an accurate marker and it is not elevated in early stages of renal dysfunction.
This is a study which will analyse all the proteins present in the blood and urine of these patients with advanced liver scarring and decompensation in order to try to identify different subsets of proteins present only when there is renal dysfunction and thus, could work as markers of renal dysfunction in patients with advanced cirrhosis. Some of these biomarkers may also help identifying markers of prognosis in patients with advanced cirrhosis and renal dysfunction.REC name
Wales REC 3
REC reference
21/WA/0325
Date of REC Opinion
26 Oct 2021
REC opinion
Unfavourable Opinion